Benchmark Upgrades BioLife Solns to Buy, Announces $25 Price Target
Portfolio Pulse from Benzinga Newsdesk
Benchmark analyst Robert Wasserman upgrades BioLife Solns (NASDAQ:BLFS) from Hold to Buy and sets a $25 price target.

May 13, 2024 | 1:42 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BioLife Solutions was upgraded by Benchmark analyst Robert Wasserman from Hold to Buy with a new price target of $25.
Analyst upgrades typically lead to a positive short-term reaction in the stock market as they reflect a positive change in the stock's outlook. The upgrade from Hold to Buy suggests a strong confidence in the company's future performance, and the setting of a $25 price target indicates a significant upside potential from the current trading price. This can attract more investors to the stock, driving up its price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100